Publications by authors named "Yau Lun Man"
Article Synopsis
- GSK3511294 is a humanized monoclonal antibody targeting interleukin-5, designed for improved performance and longer lasting effects in treating asthma.
- The Phase 1 study involved 48 patients with elevated eosinophil counts, who received either the drug or a placebo, with a focus on safety and its impact on eosinophil levels.
- Results showed that GSK3511294 was well tolerated, significantly reduced blood eosinophil counts, and had a long half-life, indicating potential for less frequent dosing compared to existing treatments.
An innovative open-label, crossover clinical study was used to investigate the excretion balance, pharmacokinetics, and metabolism of nemiralisib-an inhaled phosphoinositide 3-kinase delta inhibitor being developed for respiratory diseases. Six healthy men received a single intravenous microtracer of 10 g [C]nemiralisib with a concomitant inhaled nonradiolabeled 1000 g dose followed by an oral 800 g dose of [C]nemiralisib 14 days later. Complementary methods including accelerator mass spectrometry allowed characterization of a range of parameters including oral absorption (F), proportion of nemiralisib escaping gut wall metabolism (F), hepatic extraction (E), fraction of dose absorbed from inhaled dose (F), and renal clearance.
View Article and Find Full Text PDF